Diagnosis and therapy of alcoholic liver disease

Seminars in Liver Disease

Volumn 24, Issue 3, 2004, Pages 233-247

  Levitsky, Josh ^a   Mailliard, Mark E ^a,b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Univ of Nebraska Medical Center ^*  (United States)

^c VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Alcoholic; Antibodies; Corticosteroids; Liver disease; Monoclonal; Tumor necrosis factor alpha

Indexed keywords

ACAMPROSATE; ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CYTOCHROME P450 2E1; DISULFIRAM; GLUTATHIONE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; PENTOXIFYLLINE; PROPYLTHIOURACIL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOL WITHDRAWAL; ALCOHOLIC FATTY LIVER; ALGORITHM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL EXAMINATION; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION;

ADRENAL CORTEX HORMONES; ALCOHOL DRINKING; ANTIBODIES, MONOCLONAL; ANTIOXIDANTS; BIOPSY; DIAGNOSIS, DIFFERENTIAL; HUMANS; LIVER; LIVER DISEASES, ALCOHOLIC; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4444380869     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832937     Document Type: Review

References (173)

1. Lelbach WK. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann N Y Acad Sci 1975;252:85-105
2. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998;93:2022-2036
3. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996;23:1025-1029
4. Cleary PD, Miller M, Bush BT, et al. Prevalence and recognition of alcohol abuse in a primary care population. Am J Med 1988;85:466-471
5. Friedmann PD, McCullough D, Chin MH, Saitz R. Screening and intervention for alcohol problems. A national survey of primary care physicians and psychiatrists. J Gen Intern Med 2000;15:84-91
6. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Baltimore: Williams and Wilkins, 1986
7. Hoeksema HL, de Bock GH. The value of laboratory tests for the screening and recognition of alcohol abuse in primary care patients. J Fam Pract 1993;37:268-276
8. Skinner HA, Holt S, Schuller R, et al. Identification of alcohol abuse using laboratory tests and a history of trauma. Ann Intern Med 1984;101:847-851
9. Girela E, Villanueva E, Hernandez-Cueto C, Luna JD. Comparison of the CAGE questionnaire versus some biochemical markers in the diagnosis of alcoholism. Alcohol Alcohol 1994;29:337-343
10. Bradley KA, Bush KR, McDonell MB, et al. Screening for problem drinking: comparison of CAGE and AUDIT. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. J Gen Intern Med 1998;13:379-388
11. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993;88:791-804
12. Bush K, Kivlahan DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998;158:1789-1795
13. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 4th ed. Washington, D.C.: American Psychiatric Association; 2000
15. French SW, Nash J, Shitabata P, et al. Pathology of alcoholic liver disease. VA Cooperative Study Group 119. Semin Liver Dis 1993;13:154-169
16. Teli MR, Day CP, Burt AD, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995;346:987-990
17. Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol 1981;10:417-441
18. Cohen JA, Kaplan MM. The SGOT/SGPT ratio - an indicator of alcoholic liver disease. Dig Dis Sci 1979;24:835-838
19. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94:1018-1022
20. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-739
21. Diehl AM, Potter J, Boitnott J, et al. Relationship between pyridoxal 5′-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology 1984;86:632-636
22. Bell H, Tallaksen CM, Try K, Haug E. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: a study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res 1994;18:1103-1108
23. Stewart SH. Racial and ethnic differences in alcohol-associated aspartate aminotransferase and gamma-glutamyltransferase elevation. Arch Intern Med 2002;162:2236-2239
24. Talley NJ, Roth A, Woods J, Hench V. Diagnostic value of liver biopsy in alcoholic liver disease. J Clin Gastroenterol 1988;10:647-650
25. MacSween. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981;1:707-711
26. Velt PM, Choy OG, Shimkin PM, Link RJ. Transjugular liver biopsy in high-risk patients with hepatic disease. Radiology 1984;153:91-93
27. Levin DM, Baker AL, Riddell RH, et al. Nonalcoholic liver disease. Overlooked causes of liver injury in patients with heavy alcohol consumption. Am J Med 1979;66:429-434
28. Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987;92:208-214
29. Anderson S, Nevins CL, Green LK, et al. Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection. Dig Dis Sci 2001;46:1393-1398
30. Tamai T, Seki T, Shiro T, et al. Effects of alcohol consumption on histological changes in chronic hepatitis C: a clinicopathological study. Alcohol Clin Exp Res 2000;24(Suppl 4):106S-111S
31. Mendenhall CL, Moritz T, Rouster S, et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275. Am J Gastroenterol 1993;88:1022-1026
32. Mendenhall CL, Seeff L, Diehl AM, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). Hepatology 1991;14:581-589
33. Corrao G, Carle F, Lepore AR, et al. Interaction between alcohol consumption and positivity for antibodies to hepatitis C virus on the risk of liver cirrhosis: a case-control study. Provincial Group for the Study of Chronic Liver Disease. Eur J Epidemiol 1992;8:634-639
34. Tanaka T, Yabusako T, Yamashita T, et al. Contribution of hepatitis C virus to the progression of alcoholic liver disease. Alcohol Clin Exp Res 2000;24(Suppl 4):112S-116S
35. Worner TM, Lieber CS. Perivenular fibrosis as precursor lesion of cirrhosis. JAMA 1985;254:627-630
36. Conigrave KM, Saunders JB, Whitfield JB. Diagnostic tests for alcohol consumption. Alcohol Alcohol 1995;30:13-26
37. Stibler H, Borg S. Carbohydrate composition of serum transferrin in alcoholic patients. Alcohol Clin Exp Res 1986;10:61-64
38. Storey EL, Mack U, Powell LW, Halliday JW. Use of chromatofocusing to detect a transferrin variant in serum of alcoholic subjects. Clin Chem 1985;31:1543-1545
39. Conigrave KM, Degenhardt LJ, Whitfield JB, et al. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res 2002;26:332-339
40. Xin Y, Rosman AS, Lasker JM, Lieber CS. Measurement of carbohydrate-deficient transferrin by isoelectric focusing/ western blotting and by micro anion-exchange chromatography/radioimmunoassay: comparison of diagnostic accuracy. Alcohol Alcohol 1992;27:425-433
41. Nalpas B, Hispard E, Thepot V, et al. A comparative study between carbohydrate-deficient transferrin and gamma-glutamyltransferase for the diagnosis of excessive drinking in a liver unit. J Hepatol 1997;27:1003-1008
42. Salmela KS, Laitinen K, Nystrom M, Salaspuro M. Carbohydrate-deficient transferrin during 3 weeks' heavy alcohol consumption. Alcohol Clin Exp Res 1994;18:228-230
43. Bisson JI, Milford-Ward A. A comparison of carbohydrate deficient transferrin with other markers of alcohol misuse in male soldiers under the age of thirty. Alcohol Alcohol 1994;29:315-321
44. Anton RF, Moak DH, Latham P. Carbohydrate-deficient transferrin as an indicator of drinking status during a treatment outcome study. Alcohol Clin Exp Res 1996;20:841-846
45. Rosman AS, Basu P, Galvin K, Lieber CS. Utility of carbohydrate-deficient transferrin as a marker of relapse in alcoholic patients. Alcohol Clin Exp Res 1995;19:611-616
46. Huseby NE, Bjordal E, Nilssen O, Barth T. Utility of biological markers during outpatient treatment of alcohol-dependent subjects: carbohydrate- deficient transferrin responds to moderate changes in alcohol consumption. Alcohol Clin Exp Res 1997;21:1343-1346
47. Niemela O, Sorvajarvi K, Blake JE, Israel Y. Carbohydrate-deficient transferrin as a marker of alcohol abuse: relationship to alcohol consumption, severity of liver disease, and fibrogenesis. Alcohol Clin Exp Res 1995;19:1203-1208
48. Halm U, Tannapfel A, Mossner J, Berr F. Relative versus absolute carbohydrate-deficient transferrin as a marker of alcohol consumption in patients with acute alcoholic hepatitis. Alcohol Clin Exp Res 1999;23:1614-1618
49. Heinemann A, Sterneck M, Kuhlencordt R, et al. Carbohydrate-deficient transferrin: diagnostic efficiency among patients with end-stage liver disease before and after liver transplantation. Alcohol Clin Exp Res 1998;22:1806-1812
50. Kwoh-Gain I, Fletcher LM, Price J, et al. Desialylated transferrin and mitochondrial aspartate aminotransferase compared as laboratory markers of excessive alcohol consumption. Clin Chem 1990;36:841-845
51. Fletcher LM, Kwoh-Gain I, Powell EE, et al. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: an aid to diagnosis. Hepatology 1991;13:455-459
52. Stadheim LM, O'Brien JF, Lindor KD, et al. Value of determining carbohydrate-deficient transferrin isoforms in the diagnosis of alcoholic liver disease. Mayo Clin Proc 2003;78:703-707
53. Fagerberg B, Agewall S, Berglund A, et al. Is carbohydrate-deficient transferrin in serum useful for detecting excessive alcohol consumption in hypertensive patients? Clin Chem 1994;40:2057-2063
54. Stauber RE, Stepan V, Trauner M, et al. Evaluation of carbohydrate-deficient transferrin for detection of alcohol abuse in patients with liver dysfunction. Alcohol Alcohol 1995;30:171-176
55. Sorvajarvi K, Blake JE, Israel Y, Niemela O. Sensitivity and specificity of carbohydrate-deficient transferrin as a marker of alcohol abuse are significantly influenced by alterations in serum transferrin: comparison of two methods. Alcohol Clin Exp Res 1996;20:449-454
56. Perret R, Froehlich F, Lavanchy D, et al. Is carbohydrate-deficient transferrin a specific marker for alcohol abuse? A study in patients with chronic viral hepatitis. Alcohol Clin Exp Res 1997;21:1337-1342
57. DiMartini A, Day N, Lane T, et al. Carbohydrate deficient transferrin in abstaining patients with end-stage liver disease. Alcohol Clin Exp Res 2001;25:1729-1733
58. Huseby NE, Nilssen O, Erfurth A, et al. Carbohydrate-deficient transferrin and alcohol dependency: variation in response to alcohol intake among different groups of patients. Alcohol Clin Exp Res 1997;21:201-205
59. Lof K, Seppa K, Itala L, et al. Carbohydrate-deficient transferrin as an alcohol marker among female heavy drinkers: a population-based study. Alcohol Clin Exp Res 1994;18:889-894
60. Agelink MW, Dirkes-Kersting A, Zeit T, et al. Sensitivity of carbohydrate-deficient transferrin (CDT) in relation to age and duration of abstinence. Alcohol Alcohol 1998;33:164-167
61. Anttila P, Jarvi K, Latvala J, et al. Diagnostic characteristics of different carbohydrate-deficient transferrin methods in the detection of problem drinking: effects of liver disease and alcohol consumption. Alcohol Alcohol 2003;38:415-420
62. Davis VE, Brown H, Huff JA, Cashaw JL. The alteration of serotonin metabolism to 5-hydroxytryptophol by ethanol ingestion in man. J Lab Clin Med 1967;69:132-140
63. Voltaire A, Beck O, Borg S. Urinary 5-hydroxytryptophol: a possible marker of recent alcohol consumption. Alcohol Clin Exp Res 1992;16:281-285
64. Ponnio M, Alho H, Heinala P, et al. Serum and saliva levels of sialic acid are elevated in alcoholics. Alcohol Clin Exp Res 1999;23:1060-1064
65. Sillanaukee P, Ponnio M, Seppa K. Sialic acid: new potential marker of alcohol abuse. Alcohol Clin Exp Res 1999;23:1039-1043
66. Hernandez-Munoz R, Baraona E, Blacksberg I, Lieber CS. Characterization of the increased binding of acetaldehyde to red blood cells in alcoholics. Alcohol Clin Exp Res 1989;13:654-659
67. Nalpas B, Vassault A, Charpin S, et al. Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit. Hepatology 1986;6:608-614
68. Hultberg B, Isaksson A, Joelsson B, et al. Pattern of serum beta-hexosaminidase in liver cirrhosis. Scand J Gastroenterol 1983;18:877-880
69. Hultberg B, Isaksson A, Jansson L. Beta-hexosaminidase in serum from patients with cirrhosis and cholestasis. Enzyme 1981;26:296-300
70. Hultberg B, Braconier JH, Isaksson A, Jansson L. Beta-hexosaminidase level in serum from patients with viral hepatitis as a measure of reticuloendothelial function. Scand J Infect Dis 1981;13:241-245
71. Uppal R, Rosman A, Hernandez R, et al. Effects of liver disease on red blood cell acetaldehyde in alcoholics and non-alcoholics. Alcohol Alcohol Suppl 1991;1:323-326
72. Barr A. Drink: A Social History of America. New York: Carroll and Graf; 1999
73. Markel H. Treatment for addiction meets barriers in the doctor's office. The New York Times December 21, 2003
74. Kahan M, Wilson L, Becker L. Effectiveness of physician-based interventions with problem drinkers: a review. Can Med Assoc J 1995;152:851-859
75. Isaacson JH, Schorling JB. Screening for alcohol problems in primary care. Med Clin North Am 1999;83:1547-1563
76. Whitlock EP. Alcohol screening in primary care. BMJ 2003;327:E263-E264
77. Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine (Baltimore) 1962;41:249-276
78. Alexander JF, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971;56:515-525
79. Galambos JT. Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology 1972;63:1026-1035
80. Pares A, Caballeria J, Bruguera M, et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986;2:33-42
81. Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968;44:406-420
82. Chedid A, Mendenhall CL, Gartside P, et al. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 1991;86:210-216
83. Galambos JT. Alcoholic hepatitis: its therapy and prognosis. Prog Liver Dis 1972;4:567-588
84. Pessione F, Ramond MJ, Peters L, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003;23:45-53
85. Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 2001;7:408-413
86. Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-638
87. Capron JP, Delamarre J, Dupas JL, et al. Fasting in obesity: another cause of liver injury with alcoholic hyaline? Dig Dis Sci 1982;27:265-268
88. Lieber C. Medical and Nutritional Complications of Alcholism. New York: Plenum; 1992:97-103
89. Barak AJ, Beckenhauer HC, Badakhsh S, Tuma DJ. The effect of betaine in reversing alcoholic steatosis. Alcohol Clin Exp Res 1997;21:1100-1102
90. Ji C, Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 2003;124:1488-1499
91. Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr 2002;76:1183S-1187S
92. Sidransky H, Farber E. Liver choline oxidase activity in man and in several species of animals. Arch Biochem Biophys 1960;87:129-133
93. Kharbanda KK, Rogers DD II, Mailliard ME, et al. The comparative effects of betaine and S-adenosylmethionine on ethanol-induced changes of methionine metabolism and hepatic steatosis. Biochim Biophys Acta 2004:(in press)
94. Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-2717
95. Mendenhall CL, Tosch T, Weesner RE, et al. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986;43:213-218
96. Lohr RH. Treatment of alcohol withdrawal in hospitalized patients. Mayo Clin Proc 1995;70:777-782
97. Long CG, Williams M, Hollin CR. Treating alcohol problems: a study of programme effectiveness and cost effectiveness according to length and delivery of treatment. Addiction 1998;93:561-571
98. Hoffmann NG, Miller NS. Perspectives of effective treatment for alcohol and drug disorders. Psychiatr Clin North Am 1993;16:127-140
99. Weisner C, Ray GT, Mertens JR, Satre DD, Moore C. Short-term alcohol and drug treatment outcomes predict long-term outcome. Drug Alcohol Depend 2003;71:281-294
100. Hilton ME, Maisto SA, Conigliaro J, et al. Improving alcoholism treatment across the spectrum of services. Alcohol Clin Exp Res 2001;25:128-135
101. Graham R, Wodak AD, Whelan G. New pharmacotherapies for alcohol dependence. Med J Aust 2002;177:103-107
102. Overman GP, Teter CJ, Guthrie SK. Acamprosate for the adjunctive treatment of alcohol dependence. Ann Pharmacother 2003;37:1090-1099
103. Weinrieb RM, Van Horn DH, McLellan AT, et al. Drinking behavior and motivation for treatment among alcohol-dependent liver transplant candidates. J Addict Dis 2001;20:105-119
104. Kandel DB, Huang FY, Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend 2001;64:233-241
105. Serra MA, Escudero A, Rodriguez F, et al. Effect of hepatitis C virus infection and abstinence from alcohol on survival in patients with alcoholic cirrhosis. J Clin Gastroenterol 2003;36:170-174
106. Tabone M, Sidoli L, Laudi C, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002;9:288-294
107. Lieber CS, Weiss DG, Groszmann R, et al. I. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease: effects on drinking behavior by nurse/physician teams. Alcohol Clin Exp Res 2003;27:1757-1764
108. Lieber CS, Weiss DG, Groszmann R, et al. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease. Alcohol Clin Exp Res 2003;27:1765-1772
109. Goldberg S, Mendenhall C, Anderson S, et al. VA Cooperative Study on Alcoholic Hepatitis. IV. The significance of clinically mild alcoholic hepatitis-describing the population with minimal hyperbilirubinemia. Am J Gastroenterol 1986;81:1029-1034
110. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990;113:299-307
111. Schenker S. Alcoholic liver disease: evaluation of natural history and prognostic factors. Hepatology 1984;4(Suppl 1): 36S-43S
112. Porter HP, Simon FR, Pope CE, et al. Corticosteroid therapy in severe alcoholic hepatitis. N Engl J Med 1971;284:1250-1255
113. Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971;74:311-321
114. Blitzer BL, Mutchnick MG, Joshi PH, et al. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977;22:477-484
115. Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978;74:169-173
116. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199
117. Campra JL, Hamlin EM Jr, Kirshbaum RJ, et al. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med 1973;79:625-631
118. Depew W, Boyer T, Omata M, et al. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980;78:524-529
119. Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982;23:75-79
120. Mendenhall CL, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984;311:1464-1470
121. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methyl-prednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989;110:685-690
122. Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992;326:507-512
123. Cabr E, Rodriguez-Iglesias P, Caballeria J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000;32:36-42
124. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995;37:113-118
125. Mathurin P, Mendenhall CL, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:480-487
126. Powell LW, Axelsen E. Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut 1972;13:690-696
127. O'Keefee C, McCormick PA. Severe acute alcoholic hepatitis: an audit of medical treatment. Ir Med J 2002;95:108-109
128. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-1476
129. Ramadori G, Armbrust T. Cytokines. In: Diehl AM, Strain AJ, eds. Liver Growth and Repair. New York: Kluwer; 1998:283-294
130. Felver ME, Mezey E, McGuire M, et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990;14:255-259
131. Hill DB, Marsano L, Cohen D, et al. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992;119:547-552
132. Hanck C, Rossol S, Bocker U, et al. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol 1998;33:606-608
133. Starkel P, Bishop K, Horsmans Y, Strain AJ. Expression and DNA-binding activity of signal transducer and activator of transcription 3 in alcoholic cirrhosis compared to normal liver and primary biliary cirrhosis in humans. Am J Pathol 2003;162:587-596
134. Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-952
135. Iimuro Y, Gallucci RM, Luster MI, et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997;26:1530-1537
136. McHutchison JG, Runyon BA, Draguesku JO, et al. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991;14:96A
137. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648
138. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-425
139. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002;37:448-455
140. Narayanan Menon KV, Stadheim L, Kamath PS, et al. A Pilot Study of the Safety and Tolerability of Etanercept in Patients with Alcoholic Hepatitis. Am J Gastroenterol 2004;99:255-260
141. Poynard T, Thabut D, Chryssostalis A, et al. Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J Hepatol 2003;38:518-520
142. Berger K, Ajani UA, Kase CS, et al. Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. N Engl J Med 1999;341:1557-1564
143. Jackson VA, Sesso HD, Buring JE, Gaziano JM. Alcohol consumption and mortality in men with preexisting cerebrovascular disease. Arch Intern Med 2003;163:1189-1193
144. Volpato S, Pahor M, Ferrucci L, et al. Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: the Health, Aging, and Body Composition study. Circulation 2004;109:607-612
145. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 2001;15:1335-1349
146. Arteel GE. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 2003;124:778-790
147. McKim SE, Gabele E, Isayama F, et al. Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology 2003;125:1834-1844
148. Mezey E, Potter JJ, Rennie-Tankersley L, et al. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004;40:40-46
149. Mato JM, Camara J, Fernandez DP, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-1089
150. Torres L, Garcia-Trevijano ER, Rodriguez JA, et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. Biochim Biophys Acta 1999;1455:12-22
151. Rappaport AM, Khanna JM, Israel Y, Kalant H, eds. Liver Architecture and Microcirculation. Alcoholic Liver Pathology. Toronto: House of Lind; 1975
152. Kaplowitz N. Propylthiouracil treatment for alcoholic hepatitis: should it and does it work? Gastroenterology 1982;82:1468-1471
153. Bernstein J, Videla L, Israel Y. Hormonal influences in the development of the hypermetabolic state of the liver produced by chronic administration of ethanol. J Pharmacol Exp Ther 1975;192:583-591
154. Israel Y, Kalant H, Orrego H, et al. Experimental alcohol-induced hepatic necrosis: suppression by propylthiouracil. Proc Natl Acad Sci USA 1975;72:1137-1141
155. Orrego H, Blake JE, Blendis LM, et al. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987;317:1421-1427
156. Halle P, Pare P, Kaptein E, et al. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 1982;82:925-931
157. Orrego H, Kalant H, Israel Y, et al. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology 1979;76:105-115
158. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease (Cochrane Review). In: The Cochrane Library, issue 3. Chichester, UK: John Wiley & Sons; 2004
159. Maddrey WC. Is therapy with testosterone or anabolic-androgenic steroids useful in the treatment of alcoholic liver disease? Hepatology 1986;6:1033-1035
160. Bonkovsky HL, Fiellin DA, Smith GS, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. Am J Gastroenterol 1991;86:1200-1208
161. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane Review. Am J Gastroenterol 2002;97:1674-1684
162. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105-113
163. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998;28:615-621
164. Kershenobich D, Vargas F, Garcia-Tsao G, et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988;318:1709-1713
165. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Liver 2001;21:129-136
166. Bird G, Lau JY, Koskinas J, et al. Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology 1991;14:1097-1101
167. Trinchet JC, Balkau B, Poupon RE, et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992;15:76-81
168. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003;38(Suppl 1):S38-S53
169. Murphy F, Arthur M, Iredale J. Developing strategies for liver fibrosis treatment. Expert Opin Investig Drugs 2002;11:1575-1585
170. Enomoto N, Takei Y, Hirose M, et al. Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology 2002;123:291-300
171. Song Z, Joshi-Barve S, Barve S, McClain CJ. Advances in alcoholic liver disease. Curr Gastroenterol Rep 2004;6:71-76
172. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004;53(Suppl 1):S143-S151.
173. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100